Document:

EXHIBIT 10.21

                              SOMANTA INCORPORATED
                              --------------------

                           SERVICE PROVISION AGREEMENT
                           ---------------------------

         THIS SERVICE PROVISION AGREEMENT (this "Agreement") is by and between
Somanta Incorporated, a Delaware Corporation ("Somanta") and Gary Bower located
at 2 Monsell court, 33-41 Monsell Road, London, N4 2UH. UK ("Provider").

         WHEREAS Somanta conducts research and development in the field of
cancer therapy and prevention (the "Field"); and

         Provider is duly qualified to provide the services as described in
Exhibit A, attached hereto (the "Services") to Somanta, and Somanta desires to
engage Provider to provide such Services to Somanta in accordance with the terms
and conditions herein contained.

         NOW, THEREFORE, in consideration of the covenants and agreements
hereinafter set forth, the parties hereto agree as follows:

1.       Services: The Services to be provided by Provider to Somanta hereunder
         shall be as described in Exhibits A and A1 hereto. Exhibits A and A1
         are incorporated herein by this reference as though fully set forth
         herein.

2.       Confidentiality: Provider agrees to maintain confidential information
         of Somanta in accordance with the following terms:

         a.       "Confidential Information" shall mean all information,
                  confidential, proprietary or otherwise, provided by Somanta to
                  Provider including, without limitation, any and all technical
                  information, data, business plans, financial information,
                  information about personnel and research and development plans
                  or strategies. Confidential Information shall not include such
                  information as Provider can establish by written documentation
                  to have been generally known or to have been acquired from
                  public sources or to have been in the public domain at the
                  time of disclosure of information, in each case through no
                  fault of Provider.
<PAGE>

         b.       Nondisclosure of Confidential Information and Term of
                  Agreement: Provider agrees to hold in strict confidence and,
                  directly or indirectly, not to cause, permit or enable the
                  disclosure, publication, transfer, misappropriation or
                  revelation to any person or entity of the Confidential
                  Information, without the express prior written consent of
                  Somanta. Provider will impose upon employees or subcontractors
                  the same obligations as contained herein. Provider also agrees
                  not to use the Confidential Information for any purpose at any
                  time, other than for the sole purpose of performing the
                  Services. Provider further agrees that any disclosure of the
                  Confidential Information will only be such as is reasonably
                  necessary to the performance of the Service and will only be
                  to employees or subcontractors of Provider who are bound by
                  written agreements with Provider to maintain the Confidential
                  Information in confidence. Upon any termination or expiration
                  of this Agreement or upon the earlier request of Somanta,
                  Provider shall destroy or return immediately to Somanta, at
                  Somanta expense, all Confidential Information as defined in
                  Section ss.2a above and any and all documents or materials
                  related to the Service, including all copies in any media.
                  Somanta shall arrange for the collection of all materials in
                  all media within 30 days of termination or expiration of this
                  Agreement or upon the earlier request of Somanta. Provider's
                  obligations under this Section 2 will survive any expiration
                  or termination of this Agreement.

In the event that a court or governmental agency legally compels Provider to
disclose Confidential Information, such as that associated with a valid
discovery request, Provider shall inform Somanta of the compelled disclosure
promptly, so that Somanta may seek a protective order or other remedy or waive
compliance with this Agreement, or both. Nevertheless, Provider shall limit any
compelled disclosure of Confidential Information to that legally required.

         c.       In the event of any breach or threatened breach by Provider of
                  the provisions of Sections 2 or 3 of this Agreement, then in
                  addition to all other rights and remedies that may be
                  available at law or in equity, Somanta shall be entitled to
                  specific performance of such provisions, enforced by any court
                  having equity jurisdiction, all without the need to post a
                  bond or other security, it being acknowledged that any such
                  breach or threatened breach will cause irreparable injury to
                  Somanta.

                                       2
<PAGE>

3.       Property of Somanta:
         -------------------

         a.       Definition: For the purposes of this Agreement, "Property of
                  Somanta" shall mean "Confidential Information" and all
                  documents, materials, information, inventions (whether
                  patentable or not), data and know-how and any and all
                  intellectual property rights related thereto or arising
                  therefrom, in each case in any and all media, made, conceived
                  or developed by Provider alone or with others in the course of
                  performing the Services, except for materials related to the
                  Field which Provider can establish by written documentation
                  were the sole property of Provider or a third party prior to
                  the date of this Agreement or to have been generally known or
                  to have been acquired from public sources or to have been in
                  the public domain.

         b.       Assignment of Ownership: Provider hereby irrevocably transfers
                  and assigns any and all of its rights, title, and interest in
                  and to "Property of Somanta" as defined in Section ss.3a
                  above, and hereby agrees to execute any assignment or other
                  document that may be necessary to evidence such assignment.

4.       Termination:
         -----------

         a.       The terms of this Agreement shall commence as of 03-Nov-2005,
                  and continues until 31-Dec-2006 unless terminated pursuant to
                  subsection (b) below or unless the term hereof is extended by
                  the mutual written agreement of the parties hereto.

         b.       Notwithstanding anything to the contrary contained herein,
                  either party may terminate this Agreement with or without
                  cause at any time by giving the other party thirty (30) days'
                  prior written notice thereof. Upon any expiration or
                  termination of this Agreement, Provider shall only be entitled
                  to receive the amounts due and owing hereunder for periods
                  prior to such expiration of termination, which shall be paid
                  by Somanta within 5 business days upon submission of an

                                       3
<PAGE>

                  invoice by Provider. Provider's obligations under Sections 2
                  and 3 hereof shall survive any termination or expiration of
                  this Agreement.

5.       Compensation and Expenses: Provider's compensation and payment for the
         Service provided hereunder shall be as set forth in Exhibit A hereto.
         Provider shall invoice Somanta on provision to Somanta of Service
         "deliverable" as defined in Exhibit A. Somanta will pay Provider no
         later than fifteen (15) business days of date of Provider's invoice.
         Somanta shall reimburse Provider for all reasonable expenses and
         disbursements actually incurred which are customary and necessary for
         the provision of the Service. Provider shall provide evidence
         reasonably satisfactory to Somanta of all such expenses and
         disbursements for which reimbursement is requested.

6.       Independent Contractor: In the performance of this Agreement, it is
         mutually understood and agreed that Provider is at all times acting and
         performing as an independent contractor with, and not as an employee,
         joint venture, partner, agent, principal, officer or lessee of Somanta,
         and nothing in this Agreement shall be construed to create an
         employer-employee, agent-principal, joint venture or partnership
         relationship between Provider and Somanta. Provider shall have no
         authority to act on behalf of or to enter into any contract, or incur
         any liability for or make any representations on behalf of Somanta.

Provider shall have no claim under this Agreement or otherwise against Somanta
for Worker's Compensation, Unemployment Compensation, sick leave, group
insurance arrangements or any other employee benefits. Provider is solely
responsible for providing, at Provider's expense, all taxes, withholdings and
other similar statutory obligations or employee payroll taxes for Provider and
Provider's employees, subcontractors and Providers, and Provider will defend,
indemnify and hold Somanta harmless from any and all claims made by any entity
on account of an alleged failure by Provider to satisfy any such tax or
withholding obligations. Somanta shall not withhold on behalf of Provider
hereunder, any sums for income tax, unemployment insurance, social security or
any other withholding pursuant to any law or requirement of any government
agency. Provider shall comply at Provider's expense with all applicable
provisions of worker's compensation laws, unemployment compensation laws, social
security laws and all other applicable central or local laws, regulations and
codes relating to terms and conditions of employment required to be fulfilled by
employers or independent contractors.

                                       4
<PAGE>

7.       Insurance and Indemnification: Provider is solely responsible for
         providing, at Provider's expense, worker's compensation insurance for
         Provider and Provider's employees and subcontractors. Provider agrees
         to hold harmless and indemnify Somanta for any and all claims arising
         out of any injury, disability or death of Provider or any of Provider's
         employees and subcontractors. Provider shall indemnify, defend and hold
         Somanta, Somanta's officers, directors and shareholders, free and
         harmless from all claims, demands, losses, costs, expenses,
         obligations, liabilities, damages, recoveries and deficiencies,
         including interest, penalties, attorney's fees and costs, that Somanta
         may incur as a result of a breach by Provider of any representation,
         warranty or obligation by Provider's employees and subcontractors set
         forth under this section.

         Somanta agrees to hold harmless and indemnify Provider for any and all
         claims arising out of any injury, disability or death of Somanta or any
         of Somanta's employees and subcontractors. Somanta shall indemnify,
         defend and hold Provider, Provider's officers, directors and
         shareholders, free and harmless from all claims, demands, losses,
         costs, expenses, obligations, liabilities, damages, recoveries and
         deficiencies, including interest, penalties, attorney's fees and costs,
         that Provider may incur as a result of a breach by Somanta of any
         representation, warranty or obligation by Somanta's employees and
         subcontractors set forth under this section.

8.       No Conflict with Existing Agreements: Somanta hereby acknowledges that
         it does not desire to acquire from Provider any secret or confidential
         information which Provider may have acquired from others. Provider
         represents and warrants that Provider is free to divulge to Somanta,
         without any obligation to, or violation of any right of others, any and
         all information, practice or techniques which Provider will describe,
         demonstrate, divulge or in any manner make known to Somanta during
         Provider's performance of the Service.

9.       Dispute Resolution: In the event that any controversy or dispute arises
         between the parties hereto with respect to this Agreement, the parties
         shall use their best efforts and due diligence to reach an agreement
         for the resolution of such controversy or dispute.

                                       5
<PAGE>

10.      Miscellaneous:
         -------------

         a.       Waiver and Modification: This Agreement sets forth the entire
                  understanding of the parties with respect to the subject
                  matter hereof and supersedes all prior and contemporaneous
                  agreements and understandings between them concerning such
                  subject matter. No waiver or modification of any provision
                  hereof may be made unless by a written instrument duly
                  executed by each party. Any waiver or breach of any term or
                  condition shall not be deemed to be a waiver of any preceding
                  or succeeding breach of the same or any other terms or
                  condition. The failure of any party to insist upon strict
                  performance of any term of condition hereunder shall not
                  constitute a waiver or such party's right to demand strict
                  compliance therewith in the future.

         b.       Assignment: Provider may not assign this Agreement, or any
                  rights, duties or obligations contained herein, to any other
                  person, firm, corporation or other business entity without the
                  prior written consent of Somanta and any such assignment or
                  purported assignment shall be null and void and of no force or
                  effect. Somanta may assign this Agreement to a third party in
                  connection with a merger or sale of all or substantially all
                  of Somanta's assets with or to such third party.

         c.       Notices: All notices and other communications required or
                  permitted under this Agreement shall be in writing, served
                  personally on, delivered by recognised overnight courier or
                  mailed by certified or registered mail to the party to be
                  charged with receipt thereof at the address specified below or
                  by electronic transmission by the parties' accredited
                  providers.

                  SOMANTA:   19200 Von Karman Avenue, Irvine, CA 92612

                  PROVIDER:  Gary Bower, 2 Monsell Court,  33-4 Monsell Road,
                             London N4 2UH, UK

         d.       Severability: All sections, clauses thereof and covenants
                  contained in this Agreement are severable, and in the event
                  any of them shall be held to be invalid by any court, this

                                       6
<PAGE>

                  Agreement shall be interpreted as if such invalid Sections,
                  clauses or covenants were not contained herein.

         e.       Applicable Law: This Agreement is made and shall be governed
                  by and construed in accordance with the laws of England,
                  without regard to principles of conflicts of law.

         f.       Counterparts: This Agreement may be executed in one or more
                  counterparts, each of which shall be deemed an original, but
                  all of which together shall constitute one and the same
                  Agreement.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date herein above set forth.

ACCEPTED AND AGREED TO FOR:

Somanta Incorporated

"SOMANTA"                                "PROVIDER"

/s/ AGAMEMNON EPENETOS                      /s/ GARY BOWER
----------------------------------          ------------------------------------
By: Agamemnon Epenetos,                     By: Gary Bower
CEO

Date: November 4, 2005                      Date: November 6, 2005
      ----------------------------                ------------------------------

                                       7
<PAGE>

                                    EXHIBIT A
                                    ---------

"Services"

Those Services related to the pre-clinical and manufacturing activities by
Somanta, provided, however, that Provider shall not be required to perform
Services in a manner that would create an employment relationship with Somanta.
The provision of Services is subject to all clauses listed in under the
sub-heading Exhibit A1 "General Conditions for the Provision of Service to
Somanta by Provider".

In case of conflict between any of the terms of this Service Agreement in total
or in part with Exhibit A1, the latter will take precedence.

"Deliverables"

(i)      Provider will devote utmost knowledge and best skill to the performance
         of functions under this Agreement;

(ii)     Provider undertakes to be available to provide the service for three
         full business days per week in aggregate to the provision of services,
         subject to absences for customary vacations and for temporary illness.
         Provider may provide service for fewer or more than three business days
         in any given week in providing notice to Somanta but in any case, will
         charge Somanta for services on a daily basis. Notwithstanding these
         provisions, Provider or its employees or subcontractors may trade in
         stock, bonds, securities, commodities or real estate investments for
         their own benefit.

(iii)    Cost (Other than expenses): Provider shall be paid a gross daily sum of
         [ONE THOUSAND DOLLAR ($1,000)], payable on a monthly basis according to
         invoice by Provider to Somanta, and payable within fifteen (15)
         business days of invoice receipt. All gross daily sums to be paid
         hereunder are exclusive of any value added tax that may be applicable
         to the Services or this Agreement. The "Cost" as per this clause is
         subject to upward adjustment, from time to time, by the Board in its
         sole discretion. The provision of ongoing services by the Provider
         under this agreement is subject to the prompt payment of all invoices.

                                       8
<PAGE>

         Upon Somanta's closing of a PIPE transaction of more than $10,000,000,
         Provider shall invoice Somanta for a lump sum payment equal the [number
         of days worked since 24th August 2005] x [Gross daily rate of $1000] x
         50%. This payment will be made to Provider within ten (10) business
         days.

(iv)     Bonus: The Board of Somanta, in its sole discretion, may award the
         Provider an incentive bonus of up to thirty percent (30%) of the total
         yearly cost described in (iii) above (the "Bonus"), where "total yearly
         cost" means 3 (three) days weekly at one thousand US dollars multiplied
         by 52 (fifty two), on the achievement by Provider of certain milestones
         (the "Milestones"), as mutually agreed to by Provider and Somanta from
         time to time.

(v)      Stock Options: The Board may grant to Provider options (the "Options")
         to purchase shares Somanta's Common Stock ("Common Stock"), pursuant to
         Somanta's then in effect equity incentive plan.

(vi)     Payment Method:
         --------------

         Subject to Invoice, electronically transmitted, as follows:
         Account Name:
         Bank Address:
         IBAN:
         BIC:

                                       9
<PAGE>

                                   EXHIBIT A1

     General Conditions for the Provision of Service to Somanta by Provider

         All services provided to Clients by or on behalf of Provider, its
officers, employees and sub-contractors, hereinafter referred to in aggregate as
Provider, are subject to the following conditions agreed implicitly between
Provider and Client:

(i)      Definitions
         -----------

o        "Client" is defined as Somanta, meaning the person(s) within Somanta,
         company(ies), government(s), or institution(s) with whom Somanta may
         have dealings, for whom the Service is provided and/or to whom
         documents are addressed and/or in name of whom invoices are issued
         and/or on whose behalf the service is provided, including Somanta's
         officers, employees and sub-contractors.

o        The Service Provider is Gary Bower (including its officers, employees
         and sub-contractors).

o        Service is defined as solely advisory, for the contracted functions.
         This can be amongst others, written advice, developmental plan advice,
         advice on report, advisory opinion, advice on dossier, biologic license
         application (BLA) or new drug application (NDA).

(ii)     General Conditions
         ------------------

1.       The Client implicitly accepts these Conditions for the Provision of
         Service to Clients prior to commissioning or accepting the Service.

2.       Provider will endeavor to provide the service requested by the Client
         according to the specifications given in writing or verbally on
         commissioning the Service.

3.       Provider does not guarantee that the Service commissioned will be
         undertaken as initially planned. When changes occur in the provision of
         Service, the Client will be forewarned of the change(s) and agreement
         will be implicitly assumed unless the Client gives written notice to
         Provider before completion of the Service.

                                       10
<PAGE>

4.       Provider takes no responsibility for the integrity, veracity or content
         of reports, data, documents, background information, references,
         acceptance for publication or acceptance for submission by any entity
         for whom the Service is intended by the Client. The Client is strongly
         advised to check all contents of the Service provided and to be
         satisfied that all materials and contents, written or implied, are
         correct and adequate for the use intended by the Client.

5.       Provider will endeavor to forewarn the Client of any deficiencies in
         the materials provided by the Client and related to the Service.
         However, Provider does not guarantee the identification and forewarning
         of all or any deficiency in the materials provided by the Client.

6.       Provider provides the Service in the understanding that the Client will
         conduct a thorough review of all contents of the Service.

7.       Provider conducts internal checks of the contents of Service. However,
         the Client is strongly advised to conduct cross-checks and quality
         checks on the contents of the Service, including independent quality
         checks where appropriate.

8.       Service provision by Provider is advisory only, and the Service is
         provided for the sole use of the Client. The Client must not use the
         name of Provider, officers' names or the names of its employees and
         sub-contractors in seeking recognition, approval, publication or
         dissemination of the contents of the Service, except where such use of
         name of Provider, its officers' names or the names of its employees and
         sub-contractors are specifically allowed by separate service contract.

9.       The contents of Service provision by Provider is confidential and must
         not be divulged, disseminated or disclosed by any means to any third
         party without the written consent of Provider.

10.      The safe return of materials provided by the Client is the
         responsibility of the Client. Provider will make all materials
         available to the Client upon completion of the Service.

                                       11
<PAGE>

11.      The relationship between the Client and Provider is one of service
         provision only, and does not constitute employment.

(iii)    Communication Media Conditions
         ------------------------------

12.      Provider operates a "paperless office" policy.

13.      Clients are advised that Provider may make records of any or all its
         communications with Clients by electronic means including contact logs.

14.      Provider communications with Clients is exclusively electronic, via
         secure business internet service provider (ISP).

15.      Clients are requested to ensure they employ appropriate in-house safety
         programs and secure business ISP. It is particularly advisable that
         Clients do not use personal communications media (I.E. Hotmail, Yahoo)
         for communication with Provider. The use of unsafe media by Clients
         will imply Clients' responsibility, own risk and liability for damage
         to Provider, and damage to third parties or other Clients.

16.      It is advisable that, whenever possible, materials are supplied
         electronically for ease of document tracking, destruction or return.
         Unless otherwise requested, Provider will delete or destroy all
         documents within 3 months from completion of Service.

17.      Provider cannot accept the supply of any documentation via telefax
         transmission or normal post. Clients are kindly requested to use
         exclusively electronically safe media with appropriate firewall
         protection and anti-virus programs. Exceptionally, upon request,
         Provider may use special delivery services such as Federal Express at
         Client's own risk and cost.

18.      In the event that a Client may use non-electronic correspondence with
         Provider all postal communication must be directed to Provider's
         address for correspondence as in Section 10c).

                                       12
<PAGE>

(iv)     Financial Transactions Conditions
         ---------------------------------

19.      All financial communications and documentation between Provider and
         Clients are electronic.

20.      Unless otherwise specified in separate contractual agreement, Provider
         will normally submit monthly invoices to Client on the 20th day of the
         month.

21.      During the continuance of the Service the Client shall pay Provider the
         agreed Fees and expenses with Fees accruing as Working Days and are
         paid monthly.

22.      It is the Client's responsibility to ensure that payment of invoices
         takes place within fifteen (15) calendar days of presentation of
         invoice.

23.      Late payment by Somanta will result in a 5% automatic surcharge if the
         invoice is not paid within 30 days of presentation of the invoice.

24.      Payment date is the date when the amount invoiced is fully credited
         free of further charges or impediments into Provider's bank account.

25.      Provider presents all invoices to Clients electronically. Therefore,
         Provider invoices do not contain physical signatures. Clients are
         advised to consider Provider invoices only if delivered via Provider's
         own ISP. Exceptionally, Provider personnel may deliver invoices by
         hand, for expedience if personnel are on site, but electronic records
         are always kept.

26.      All Provider Services are subject to Value Added Tax (VAT) at variable
         rates set by the UK government. VAT is charged on the total of the
         invoiced amount.

27.      Certain exemptions exist for the application of VAT, such as invoices
         to Clients based outside the UK or outside the European Union (EU).

28.      Clients based within in the EU, except the UK, must provide their EU
         VAT registration number to be exempted from UK VAT. Clients are advised
         that Provider does not guarantee the maintenance of the current VAT
         exemptions within the EU and that different Member States may apply
         different limits to VAT exemption when a Client purchases Services from
         another Member State.

                                       13
<PAGE>

29.      Provider does not accept cash as means of payment for its Services.
         Clients are requested to issue only or interbank transfers into
         Provider's bank account.

30.      All payments must be made in the name of Provider. Interbank transfers
         must always be made into the account specified in Exhibit A.

31.      Clients will reimburse any expenses reasonably incurred by Provider,
         its officers, employees and sub-contractors when such expenses are
         incurred during the provision of the Services.

32.      All expenses will be accompanied by appropriate evidence of expense
         whenever possible, reasonable and applicable within the array of
         Services provided and related expenses.

33.      Clients shall also reimburse Provider for the following general
         expenses anticipated as frequent in the fulfillment of Services:
         airfares in scheduled economy class for destinations inside the EU or
         within fewer than 4 hours' flight time from Heathrow; airfares in
         scheduled business class for destinations outside the EU or within more
         than 4 hours' flight time from Heathrow; hotel accommodation (4-star
         rating or higher according to www.expedia.co.uk); adequate subsistence
         costs during business travel on behalf of the Client; telephone costs
         for calls using Provider's fixed or mobile lines; any other reasonable
         expense incurred during provision of Services.

34.      Provider shall provide only electronic copies of evidence of expense
         (receipts), usually in pdf format or similar media, or occasionally
         photocopies for expense items that have a receipt, except for telephone
         call costs which will be presented as total time in hours with total
         cost except for Clients who provide their own call-charge cards for
         their business calls.

                                       14CONFIDENTIAL TREATMENT REQUESTED                                   EXHIBIT 10.22

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 OF THE SECURITIES ACT OF 1933
CONFIDENTIAL TREATMENT IS REQUESTED AND IS NOTED WITH "[CONFIDENTIAL TREATMENT
REQUESTED]." AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN PREVIOUSLY FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION.

                          AGREEMENT REGARDING ACADEMIC
                                 CLINICAL STUDY
                                     BETWEEN
                          THE CANCER RESEARCH INSTITUTE
                                 OF CONTRA COSTA
                                       AND
                                 SOMANTA LIMITED

<PAGE>
                        CONFIDENTIAL TREATMENT REQUESTED

                   AGREEMENT REGARDING ACADEMIC CLINICAL STUDY

         THIS AGREEMENT REGARDING ACADEMIC CLINICAL STUDY (the "Agreement") is
entered into as of August 18, 2005 (the "Effective Date") by and between SOMANTA
LIMITED, a corporation organized under the laws of England ("Somanta"), and THE
CANCER RESEARCH INSTITUTE OF CONTRA COSTA, a non-profit research institution
("CRICC"), each individually referred to in this Agreement as a "Party" and both
collectively as the "Parties".

                                    RECITALS

         WHEREAS, Somanta is the sublicensee under that certain Patent and
Know-how Exclusive Sublicense Agreement dated as of even date herewith with
Immunodex, Inc. ("Immunodex"), licensee of CRICC, related to certain patents
covering the antibody know as HuBrE-3 and certain patents covering the antibody
known as HuMc-3;

         WHEREAS, CRICC desires to continue to coordinate a Phase I-II clinical
trial with escalating dose protocol of 90Y-HuBrE-3 and/or protocol combining
90Y-HuBrE-3 and Xeloda to be conducted within the United States of America (the
"Clinical Trial"); and

         WHEREAS, Somanta desires to provide funding to CRICC to enable the
Clinical Trial, subject to the terms and conditions set forth herein.

                                    AGREEMENT

         NOW, THEREFORE, in consideration of the mutual covenants and promises
set forth herein, the parties hereby agree as follows:

         1.       Selection of Clinical Trial Site. CRICC shall identify an
appropriate institution (or institutions) that has the experience, facilities
and resources to undertake the Clinical Trial. CRICC shall enter into an
agreement with each applicable institution which shall, among other things,
require such institution to undertake the Clinical Trial in accordance with
generally accepted good clinical practices that are consistent with the Clinical
Trial's approved protocol. Before any patient is treated in the Clinical Trial,
the institution conducting the Clinical Trial shall have received approval from
its institutional review board and any relevant human subject protection
committee.

         2.       Provision of Materials. CRICC, or Immunodex, shall provide
[CONFIDENTIAL TREATMENT REQUESTED] HuBrE-3 for the Clinical Trial to each
applicable institution in accordance with any applicable regulations or consents
of the U.S. Food and Drug Administration.

         3.       Payment Schedule. In connection with the conduct of the
Clinical Trial and in consideration for the services to be performed by CRICC in
connection therewith, Somanta will make payments to CRICC in accordance with
this Section 3. At such time as Somanta shall have received a completed case
reporting form for a patient in accordance with the Clinical Trial protocol,
Somanta will (i) [CONFIDENTIAL TREATMENT REQUESTED] CRICC in an amount equal to
[CONFIDENTIAL TREATMENT REQUESTED] conducting the Clinical Trial with respect to

                                       1
<PAGE>
                        CONFIDENTIAL TREATMENT REQUESTED

such [CONFIDENTIAL TREATMENT REQUESTED], plus (ii) [CONFIDENTIAL TREATMENT
REQUESTED]. The parties acknowledge and agree that CRICC is currently obligated
to pay [CONFIDENTIAL TREATMENT REQUESTED] per patient in connection with the
Clinical Trial. To the extent CRICC engages additional institutions in
connection with conduct of the Clinical Trial, CRICC shall use reasonable
efforts to negotiate a price to be paid by CRICC for each patient included in
the Clinical Trial at such institution shall not exceed the amount to be paid to
the [CONFIDENTIAL TREATMENT REQUESTED] per patient.

         4.       Supervision of Trial. The Parties acknowledge and agree that
the Clinical Trial shall be supervised by a committee comprised of Drs. Jerry
Peterson and Roberto Ceriani and each applicable principal investigator at the
Clinical Trial site institution(s) (the "Committee"). Drs. Peterson and Ceriani,
to the extent permitted by the clinical trial site, shall have direct access to
all data produced in and related to the Clinical Trial and the ability to
interact with all scientific and clinical members of the Clinical Trial at each
institution in addition to each applicable principal investigator. In addition,
CRICC or the Clinical Trial site will file, or cause to be filed, any and all
reports related to the Clinical Trial as required by applicable law (the "FDA
Reports").

         In view of Drs. Peterson's and Ceriani's expertise in the area of the
conduct of clinical trials and longstanding involvement in the research and
clinical work that has lead to the Clinical Trial, and to avoid any lack of
coordination or confusion, Somanta shall, if it receives any inquiry from a
clinical site or clinical investigator participating in the Clinical Trial
regarding a regulatory, clinical or technical matter, refer such person to one
of Drs. Peterson and Ceriani. Drs. Peterson and Ceriani will keep Somanta
informed of the resolution of such inquiries.

         5.       Confidentiality.
                  ---------------

                  (a)      Confidentiality Obligation. During the term of this
Agreement and for a period of five (5) years thereafter, the parties hereto will
maintain all Confidential Information (as defined below) as confidential and
will not disclose any Confidential Information or use any Confidential
Information for any purpose, except (i) as expressly authorized by this
Agreement, (ii) as required by law, rule, regulation or court order (provided
that the Disclosing Party (as defined below) uses reasonable efforts to obtain a
protective order or to seek confidential treatment of any such information
required to be disclosed), or (iii) to its employees, agents, consultants and
other representatives who require access to such information to accomplish the
purposes of this Agreement so long as such persons are under an obligation of
confidentiality no less stringent than as set forth herein. Notwithstanding
anything to the contrary herein, (A) CRICC acknowledges and agrees that Somanta
may disclose Confidential Information to (i) the U.S. Food and Drug
Administration ("FDA") and/or corresponding foreign regulatory authorities in
connection with the regulatory filings related to the development of Somanta
products, and (ii) potential investors of Somanta in connection with such
investors' due diligence investigation of Somanta; and (B) Somanta acknowledges
and agrees that CRICC may disclose Confidential Information to the FDA in
connection with the filing of the FDA Reports.

                  (b)      Definition. For purpose of this Agreement,
"Confidential Information" means all information provided by or on behalf of one
Party (the "Disclosing Party") to the other Party (the "Receiving Party") in

                                       2
<PAGE>
                        CONFIDENTIAL TREATMENT REQUESTED

connection with the Clinical Trial and all data and information developed
pursuant to the Clinical Trial, whether in oral, written, graphic or electronic
form. Notwithstanding the foregoing, Confidential Information will not include
any information which the Receiving Party can prove by competent written
evidence: (i) is now, or hereafter becomes, through no act or failure to act on
the part of the Receiving Party, generally known or available; (ii) is known by
the Receiving Party at the time of receiving such information; (iii) is
hereafter furnished to the Receiving Party by a third party, as a matter of
right and without restriction on disclosure; (iv) is the subject of a written
permission to disclose provided by Disclosing Party, or (v) is published in
accordance with Section 6. The Receiving Party may disclose the Confidential
Information to comply with applicable governmental regulations, provided that if
such disclosure is required, Receiving Party will, to the extent practicable,
give reasonable advance notice to Disclosing Party of such disclosure
requirement and will use its best efforts to secure confidential treatment of
such information required to be disclosed.

         6.       PUBLICATIONS. In the event that either Party and/or their
respective employees, agents, consultants or other representatives, or those of
a clinical site or clinical investigator participating in the Clinical Trial,
wish to make a publication (including any oral disclosure made without
obligation of confidentiality) relating to the Clinical Trial such Party will
deliver to the other Party a copy of the proposed written publication or an
outline of such oral disclosure at least thirty (30) days prior to submission
for publication or presentation, as applicable. Such other Party will have the
right (a) to propose modifications to the publication for protection of
Confidential Information or other reasons (however, to avoid any doubt, beyond
the delay time period set forth herein to enable patent filing as set forth
below, clinical investigators, including without limitation Drs. Peterson and
Ceriani, shall not be prohibited from publishing data, results and information
from the Clinical Trial), and (b) to request a delay in publication in order to
protect patentable information. If such other Party requests such a delay, the
Party desiring to publish will delay submission or presentation of the
publication for a period of sixty (60) days to enable patent applications
protecting such other Party's rights in such information to be filed. Upon the
expiration of thirty (30) days from delivery of the proposed written publication
or the outline of any oral disclosure, as applicable, to such other Party the
Party desiring to publish will be free to proceed with the written publication
or the oral presentation, respectively, unless such other Party has requested
the delay described above. In no event shall a Party publish any Confidential
Information in such proposed publication without the other Party's prior written
consent. In addition, CRICC shall require each institution conducting the
Clinical Trial to enter into covenants with respect to Confidential Information
and publications substantially similar to those contained in Sections 5 and 6
this Agreement.

         7.       Rights to Data.
                  --------------

                  (a)      No License. Except as expressly set forth in this
Agreement, nothing herein shall be construed as a license, assignment or any
other right to practice or use any invention or other intellectual property of
any Party to this Agreement.

                  (b)      Results and Data. Somanta shall be provided with, and
shall have the right to access and use, all data collected or generated in the
course of conducting the Clinical Trial, including, without limitation, records,
reports, specimens, and other work product generated by or on behalf of any
principal investigator in the course of performing the Clinical Trial, whether

                                       3
<PAGE>
                        CONFIDENTIAL TREATMENT REQUESTED

in written, graphic or electronic form or contained in any computer database or
in any computer readable form ("Data"). CRICC agrees to attempt to require the
principal investigator to ensure the accuracy, completeness, legibility and
timeliness of all Data provided.

          8.      INDEMNIFICATION.
                  ---------------

                  (a)      By CRICC. CRICC will defend, indemnify and hold
harmless Somanta and its directors, officers, agents, consultants and employees,
from and against all claims, demands, actions, suits and proceedings that may be
brought or instituted by a third party ("Claims"), and all judgments, damages,
losses, liabilities, costs and expenses resulting therefrom, resulting directly
from (i) [CONFIDENTIAL TREATMENT REQUESTED], or (ii) [CONFIDENTIAL TREATMENT
REQUESTED].

                  (b)      By Somanta. Somanta will defend, indemnify and hold
harmless CRICC, Immunodex and their trustees, directors, officers, agents,
consultants and employees (collectively, the "CRICC Indemnitees") as well as
each institution at which the Clinical Trial takes place (including, without
limitation, their directors, officers, agents, consultants and employees ("Site
Indemnitees"), from and against all Claims, and all judgments, damages, losses,
liabilities, costs and expenses (including without limitation attorneys' fees)
resulting therefrom, arising out of or resulting from the Clinical Trial, except
solely to the extent resulting directly from (i) the gross negligence,
recklessness or willful misconduct of any CRICC Indemnitee, (ii) any failure by
any CRICC Indemnitee to perform his or her obligations under this Agreement in
compliance with applicable laws, rules or regulations, or solely with respect to
indemnification of the Site Indemnitees (iii) (a) the gross negligence,
recklessness or willful misconduct of any Site Indemnitee, or (b) any failure by
any Site Indemnitee to perform his or her obligations under the written
agreement contracting for such obligations, in compliance with applicable laws,
rules or regulations.

                  (c)      Procedure. In the event either Party seeks
indemnification under this Section 8, it will inform the other Party of a Claim
as soon as reasonably practicable after it receives notice of the claim, will
permit the other Party to assume direction and control of the defense of the
Claim (at the indemnifying Party's expense) (including the right to settle the
Claim solely for monetary consideration), and will cooperate as requested (at
the expense of the other Party) in the defense of the Claim. Any failure to
promptly provide notice as required in the foregoing sentence shall only relieve
the indemnifying Party of its indemnification obligation to the extent the delay
prejudices defense of the Claim.

         9.       REPRESENTATIONS AND WARRANTIES; LIMITATION OF LIABILITY.
                  -------------------------------------------------------

                  (a)      Authority. Each Party represents and warrants that it
has full power and authority to enter into this Agreement and to perform all of
its obligations hereunder.

                  (b)      Due Authorization. Each Party hereby represents and
warrants that such Party is duly authorized to execute and deliver this
Agreement and to perform its obligations hereunder.

                  (c)      Binding Agreement. Each Party hereby represents and
warrants that this Agreement is a legal and valid obligation binding upon it and
is enforceable in accordance with its terms. The execution, delivery and

                                       4
<PAGE>
                       CONFIDENTIAL TREATMENT REQUESTED

performance of this Agreement by such Party does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a Party
or by which it may be bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having authority over it.

                  (d)      Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET
FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY TO
THE OTHER PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION,
ANY WARRANTY OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE.

         10.      TERM AND TERMINATION.
                  --------------------

                  (a)      Term. The term of this Agreement will commence on the
Effective Date and will expire upon completion of the Clinical Trial, unless
terminated earlier as provided herein or extended by mutual written agreement of
the parties. "Completion of the Clinical Trial" for those purposes will be
deemed to occur the moment all data from the Clinical Sites has been received,
reviewed, and submitted by CRICC and approved by Somanta and the final/closure
report is filed with the FDA.

                  (b)      Termination. This Agreement may be terminated by
either Party with thirty (30) days advance written notice upon material breach
of this Agreement by the other Party, unless such breach is cured within such
thirty (30) day period. This Agreement may be terminate by the mutual agreement
of the Parties. This Agreement will terminate automatically if: (i) at least ten
(10) patients participating in the Clinical Trial are not dosed within
twenty-four (24) months after the date of this Agreement on the date that is
twenty-four (24) months after the date of this Agreement, or (ii) Somanta
becomes obligated to make payments to Immunodex pursuant to Section 8.4.2(f) of
the Patent and Know-how Exclusive Sublicense Agreement of even date herewith
between Somanta and Immunodex (the "Sublicense Agreement") on the date such
obligation arises, or (iii) if the Sublicense Agreement is terminated in its
entirety or as to BrE-3 and Somanta is not obligated to make payments to
Immunodex pursuant to Section 8.4.2(f) of the Sublicense Agreement pursuant to
the terms of Section 8.4.2(f) of the Sublicense Agreement (i.e., Somanta has
already paid for at least ten (10) patients pursuant to this Agreement) on the
date of such termination of the Sublicense Agreement or portion thereof.

                  (c)      Survival Upon Termination. Expiration or termination
of this Agreement will not relieve the parties of any obligation accruing prior
to such expiration or termination. Sections 5, 6, 7, 8, 9, 10(c) and 11 will
survive termination of this Agreement.

         11.      MISCELLANEOUS
                  -------------

                  (a)      Assignment. Except as expressly provided hereunder,
neither this Agreement nor any rights or obligations hereunder may be assigned
or otherwise transferred by either Party without the prior written consent of
the other Party; provided, however, that Somanta may assign this Agreement and
its rights and obligations hereunder without such consent to the extent it has
the right to assign the Patent and Know-how Exclusive Sublicense Agreement of
even date herewith between it and Immunodex, solely to its assignee of such
license agreement. The rights and obligations of the parties under this

                                       5
<PAGE>
                        CONFIDENTIAL TREATMENT REQUESTED

Agreement will be binding upon and inure to the benefit of the successors and
permitted assigns of the parties. Any assignment not in accordance with this
Agreement will be void.

                  (b)      Governing Law. This Agreement will be governed by,
and construed and enforced in accordance with, the laws of the State of
California, as such laws apply to agreements between California residents
performed entirely within the State of California.

                  (c)      Waiver. Except as specifically provided for herein,
the waiver from time to time by either Party of any right or failure to exercise
any remedy will not operate or be construed as a continuing waiver of the same
right or remedy or of any other of such Party's rights or remedies provided
under this Agreement.

                  (d)      Severability. In case any provision of this Agreement
will be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions will not in any way be affected or
impaired thereby.

                  (e)      Entire Agreement; Amendment. This Agreement sets
forth all of the agreements and understandings between the parties hereto with
respect to the subject matter hereof, and supersedes and terminates all prior
agreements and understandings between the parties with respect to the subject
matter hereof, including, without limitation that certain Agreement between
Somantis and the Cancer Research Institute of Contra Costa (CRICC) for
Conduction of Academic Clinical Trial with 90Y-HuBrE3, and 90Y-HuBrE3 and
Chemotherapy dated October 13, 2003 between Somantis Limited and the Cancer
Research Institute of Contra Costa, as amended or modified to date. There are no
agreements or understandings with respect to the subject matter hereof, either
oral or written, between the parties other than as set forth herein. Except as
expressly set forth in this Agreement, no subsequent amendment, modification or
addition to this Agreement will be binding upon the parties hereto unless
reduced to writing and signed by the respective authorized officers of each
Party. To avoid any doubt, this Agreement in no way amends or supersedes the
Patent and Know-how Exclusive Sublicense Agreement of even date herewith between
Somanta and Immunodex.

                  (f)      Independent Contractors. It is expressly agreed that
the parties will be independent contractors and that the relationship between
the parties will not constitute a partnership, joint venture or agency of any
kind. Neither Party will have the authority to make any statements,
representations or commitments of any kind, or to take any action, which will be
binding on the other Party, without the prior written consent of the other
Party.

                  (g)      Notice. All notices and other communications provided
for hereunder will be in writing and will be mailed by first-class, registered
or certified mail, postage paid, or delivered personally, by overnight delivery
service or by facsimile, with confirmation of receipt, addressed as follows:

         If to Somanta:       Somanta Incorporated
                              10 Old Course Drive
                              Newport Beach, CA 92660
                              Attention:  Terrance Bruggeman
                              Facsimile:  949-706-3698

                                       6
<PAGE>
                        CONFIDENTIAL TREATMENT REQUESTED

         If to CRICC:         Cancer Research Institute of Contra Costa,
                              New York Office
                              [CONFIDENTIAL TREATMENT REQUESTED]

         Either Party may by like notice specify or change an address to which
notices and communications will thereafter be sent. Notices sent by facsimile
will be effective upon confirmation of receipt, notices sent by mail or
overnight delivery service will be effective upon receipt, and notices given
personally will be effective when delivered.

                  (h)      Headings. The captions contained in this Agreement
are not a part of this Agreement, but are merely guides or labels to assist in
locating and reading the several Sections hereof.

                  (i)      Counterparts. This Agreement may be executed in two
or more counterparts, by facsimile, or both, each of which will be deemed an
original, but all of which together will constitute one and the same instrument.

                                       7
<PAGE>
                        CONFIDENTIAL TREATMENT REQUESTED

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
Effective Date.

SOMANTA LIMITED                          THE CANCER RESEARCH INSTITUTE OF
                                         CONTRA COSTA

By: /s/ TERRANCE J. BRUGGEMAN            By:  /s/ JERRY A. PETERSON
    --------------------------------          ----------------------------------
Name:   Terrance J. Bruggeman            Name:    Jerry A. Peterson
    --------------------------------          ----------------------------------
Title:  Chairman                         Title:   Chief Executive Officer
      ------------------------------            --------------------------------

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]